Dr. Che is one of the co-founders of Sihuan Pharmaceutical. He is responsible for the overall management, strategic planning and business development of the Group and is instrumental to our growth and business expansion since our establishment in 2001. Prior to the establishment of Sihuan Pharmaceutical, Dr. Che was a medical doctor/neurologist for more than eight years and is highly experienced in sales and marketing of pharmaceutical products and in managing pharmaceutical companies.
From 1997 to 2001 Dr. Che was general manager of Hainan Kang Tong Pharmaceutical Co., Ltd (海南康通醫藥有限公司) where he was in charge of the company's overall management. From 1995 to 1997, Dr. Che was assistant general manager and vice manager (marketing) of Shenzhen City New Special Pharmaceutical Products Co., Ltd. (深圳市新藥特藥有限公司) where he was responsible for the marketing and overall management of the company's business. Between 1993 and 1995, Dr. Che was product promotions manager of Shenzhen City Healthcare Pharmaceutical Company (深圳市健安醫藥公司) and East China Regional manager, in charge of sales and marketing. From 1991 to 1993, Dr. Che held the position of chief neurologist and lecturer in First Military Medical University, Zhu Jiang Hospital, Guangzhou City, PRC (廣州市第一軍醫大學珠江醫院). Dr. Che was a neurologist and an assistant lecturer at the Fourth Military Medical University in Xi'an City, PRC (西安市第四軍醫大學) from 1990 to 1991 and at the Fourth Military Medical University, Xi Jing Hospital in Xi'an City, PRC from 1984 to 1987.Dr. Che is the vice-chairman of several committees and associations including, China Political Science Training Centre (中國政策科學培訓中心), China Medical Economics Magazine Board (中國藥物經濟學染志社) and the Hainan Entrepreneurs Association (海南省企業家協會). Dr. Che is also a deputy supervisor of the Hainan Food and Drug Working Committee in the Hainan Entrepreneurs Association (海南省企業家協會食品藥業工作委員會) as well as a specially appointed research member of the China Enterprise Reform and Development Research Institute (中國企業改革發展研究院). In 2006, he was named one of the Top 10 New and Enterprising Businessmen (首屆海南省工商業十大新銳人物) in Hainan Province by the Hainan Province Commerce Association (海南省商業聯合會), the Hainan Industry & Economics Association (海南省工業經濟聯合會) and the Evaluation Committee of Top 10 Leading Businessmen and Top 10 New and Enterprising Businessmen in Industry and Commerce in Hainan (海南省工商業十大領軍人物十大新銳人物評委會). Dr. Che was appointed President of Commerce Chamber of Hainan in 2009. Dr. Che obtained his Bachelor of Medicine (Aviation) (航空醫學) and Master of Medicine (Neurology) from the Fourth Military Medical University, Xi'an City, PRC, in 1984 and 1990 respectively. He also obtained an Executive Master of Business Administration from China Europe International Business School (中歐國際工商學院) in 1999.

Dr. Guo is deputy chairman of the Group. He is also a co-founder of the Group, responsible for the overall operations of the Group and its research and development activities, with a focus on strategic planning in relation to mergers and acquisitions and product collaborations. He has also assumed the responsibilities of overseeing the overall operation of Shenzhen Sihuan following its acquisition by the Group in 2007. Dr. Guo has been instrumental to the Group's growth and business expansion since our establishment in 2001. Prior to the establishment of Sihuan Pharmaceutical, Dr. Guo was a general surgeon for more than four years. He also has extensive experience in the sales and marketing of pharmaceutical products.
From 1998 to 2001, Dr. Guo held the position of assistant general manager in Hainan Kang Tong Pharmaceutical Co., Ltd. (海南康通醫藥有限公司) where he oversaw sales of pharmaceutical products. From 1995 to 1998, he was a manager of Shenzhen City New Special Pharmaceutical Products Co., Ltd. (深圳市新藥特藥有限公司) in Heilongjiang province, in charge of marketing. Between 1993 and 1995, Dr. Guo worked for Shenzhen City Healthcare Pharmaceutical Company (深圳市健安醫藥公司) where he was a manager in charge of marketing in Heilongjiang. From 1992 to 1993, Dr. Guo was chief surgeon at Guangzhou Military 177 Hospital. Dr. Guo was a surgeon and assistant lecturer in the Fourth Military Medical University, Tang Du Hospital, Xi'an City, China from 1986 to 1989. Dr Guo graduated from the Fourth Military Medical University in Xi'an City with a Master of Medicine (General Surgery) degree in 1992 and a Bachelor of Medicine degree 1986.

Mr. Meng has extensive experience in the pharmaceutical industry in the areas of marketing, sales and distribution of pharmaceutical products. He joined the Group in 2002 and is responsible for public affairs and governmental relations as well as sales and marketing in certain regions.From 1997 to 2001, Mr. Meng was a provincial manager at Shenzhen City Wan Ze Pharmaceutical Co., Ltd. (深圳市萬澤醫藥有限公司) overseeing sales of pharmaceutical products. Between 1987 and 1997, Mr. Meng was departmental head of Jilin Materials Bureau (吉林省物資局) where he was responsible for production materials planning and allocation. Mr. Meng was conferred the title of Economist by the Jilin Provincial Government in 1993. Mr. Meng obtained a Graduate Certificate in Management Engineering from Huazhong Engineering College (華中工學院) (now Huazhong University of Science and Technology (華中理工大學))in 1987. He undertook a one-year postgraduate business administration course in Beijing University in 2005.

Dr. Zhang Jionglong - Non-executive DirectorDr. Zhang has more than nine years of experience as a medical doctor. Between 1992 and 2005, Dr. Zhang held the position of general manager in Shenzhen Tai'an Pharmaceutical Development Co., Ltd. (深圳市太安醫業發展有限公司), a company specializing in the distribution and sale of medical supplies, and hospital and healthcare equipment. As general manager, Dr. Zhang was responsible for the management, operations and strategic planning of the company. From 1983 to 1992, Dr. Zhang worked as a medical doctor in Shenzhen City People's Hospital, one of the largest hospitals in Shenzhen. Dr. Zhang obtained a Graduate Certificate in Medical Treatment from Shantou Medical College in China (汕頭醫學專科學院) (now Shantou University Medical College (汕頭大學醫學院)) in 1983. In 1992, Dr. Zhang was conferred the title of Chief Physician by the Shenzhen City Title Conferment Reform Leadership Group (深圳市職稱改革領導小組).

Mr. Sun is currently a managing director of Morgan Stanley Asia Limited and leads Morgan Stanley Private Equity Asia's China investments. He is currently a non-executive director of China Shanshui Cement Group Limited, a company listed on the Hong Kong Stock Exchange (Stock Code: 691) as well as China Flooring Holding Company Limited. Mr. Sun has been with Morgan Stanley Asia Limited since 2000 and worked on a wide range of mergers and acquisitions in Greater China in the Investment Banking Division of Morgan Stanley Asia Limited prior to joining Morgan Stanley Private Equity Asia. From September 1996 to March 2000, he was a corporate attorney specialising in mergers and acquisitions with Simpson Thacher & Bartlett in New York and Hong Kong. Mr. Sun received a B.S.E. in Chemical Engineering, magna cum laude, from the University of Michigan in 1993 and a J.D., cum laude, from the University of Michigan Law School in 1996.

Mr. Huang is currently an executive director of Morgan Stanley Asia Limited and a senior member of Morgan Stanley Private Equity Asia focusing on China investments. Mr. Huang has been with Morgan Stanley Asia Limited since 2003 and advised on a broad range of technology, media and communications transactions across Greater China for Morgan Stanley Asia Limited's Investment Banking Division prior to joining Morgan Stanley Private Equity Asia. Prior to joining Morgan Stanley Asia Limited, Mr. Huang was with Morgan Stanley's Investment Banking Division in New York and Merrill Lynch in their Financial Institutions Investment Banking Group in New York. Mr. Huang is a director of CIMIC Industrial Group Ltd and its subsidiary, Shanghai CIMIC Tiles Co., Ltd, which is a Shenzhen-listed company (Stock Code: 002162), and China Flooring Holding Company Limited. Mr. Huang received a B.A. in Economics and East Asian Studies from Yale University in 1997 and an M.B.A. from Harvard Business School in 2002.

Mr. Sun has been an independent non-executive director and non-executive chairman of Solomon Systech International Limited (Stock Code: 2878) from February 2004, an independent non-executive director of China Railway Group Limited (Stock Code: 390) from August 2007 and an independent non-executive director of Trinity Limited (Stock Code: 891) from October 2008 (all of which are listed on the Stock Exchange). He is currently a vice chairman of the Chamber of Hong Kong Listed Companies and was, formerly its Honorary Chief Executive Officer from December 2002 to September 2004. He was a member of the Takeovers & Mergers Panel and the Takeovers Appeal Committee of the Securities and Futures Exchange from 1995 to 1997 and from 1999 to 2001, Deputy Convenor/Chairman of the Listing Committee from 1996 to 2002 and a member of the Council of the Stock Exchange from 1995 to 2000. He was previously the Senior Country Officer and Head of Investment Banking for Hong Kong of JPMorgan Chase from 2000 to 2002. He also previously served as an executive director and chief executive officer of Value Convergence Holdings Limited (Stock Code: 821) from August 2006 to October 2009, executive director of SW Kingsway Capital Holdings Limited (Stock Code: 188) from September 2004 and May 2006 (both of which are listed on the Stock Exchange), group executive director and co-head of Investment Banking of Jardine Fleming Holdings Limited from 1996 to 2000, independent non-executive director of Link Management Limited between September 2004 and July 2007, and independent non-executive director of Everbright Pramerica Fund Management Co., Ltd. Mr. Sun graduated from the Wharton School of the University of Pennsylvania, United States with a bachelor of science degree in economics in 1981. Mr. Sun is a fellow of the Chartered Association of Certified Accountants, United Kingdom, and a fellow of the Hong Kong Institute of Certified Public Accountants.

Mr. Bai has more than 30 years of experience in pharmaceutical products management and drugs supervision and is familiar with the development of the pharmaceutical industry. He was involved in drafting and formulating the drug rules in the pharmaceutical industry. Mr. Bai is currently president of China OTC Association (中國非處方藥物協會會長) and vice president of the enterprise management branch under the Chinese Medical Association (中國醫藥企業管理協會副會長). Mr. Bai obtained a Graduate Certificate in Organic Synthesis from Beijing University of Technology in 1968. Between 1967 and 1997, Mr. Bai held the positions of technician and secretary in Factory No. 12 of Shenyang Northeast Pharmaceutical Main Factory Workshop (瀋陽東北製藥總廠十二車間), personnel director in State Pharmaceutical Administration and Production Association (國家醫藥管理總局生產調度局任人事司), deputy director in the Technical Department (技術幹部處副處), board officer, deputy director of personnel and deputy director and director of Politics and Law departments of the State Pharmaceutical Administration and Production Association (國家醫藥管理局人事司副司長，政法司副司長) and chief engineer in China Xinxing Medical and Pharmaceutical Technology Development Corporation (中國新興醫藥科技發展總公司). Before Mr. Bai's retirement in March 2005, he served as director of drug safety supervision division of State Food and Drug Administration (國家食品藥品監督管理局任藥品安全監管司司長) where he was primarily responsible for national pharmaceutical research and production and supervision of special drugs. Mr. Bai has acted as an independent director of Shanghai Pharma Group (上藥集團公司) since January 2010 and of Gansu Duyiwei Biological Pharmaceutical Co., Ltd. (甘肅獨一味生物製藥股份有限公司) (listed on the Shenzhen Stock Exchange; Stock code: 002219) since April 2010.

Mr. Xu has more than 40 years of experience in the research of pharmaceutical, biological and biochemical drugs. Mr. Xu obtained a graduate certificate in Biological Chemistry from Fudan University in 1965. Between 1965 and 2005, Mr. Xu held the positions of assistant researcher and researcher of biological and pharmaceutical products and director of genetics engineering of the pharmaceutical products branch of the Ministry of Health, Pharmaceutical and Biological Products (衛生部藥品生物製品檢定所). From 2005 to 2007, Mr. Xu held the positions of researcher and deputy director of the research centre of State of Standardising Pharmaceutical and Biological Products (中國藥品生物製品標準化研究中心). Before Mr. Xu's retirement in January 2008, he served as deputy director and researcher at Ministry of Pharmaceutical and Biological Products (中國藥品生物製品檢定所).